Member Info for SGD27

https://www.vo%78markets.co.uk/media/5e8c6a540a204d0017843dd5/

Unlikely that BJ would be put on a trial with 50% chance of placebo. (Unless of course there are unblinded doses available.)

SNG001 is not part of Recovery. (This was clarified days ago, so understandable that some new people might not be aware.)

@Ghia : RE the COPD trial, they said this in the 18 March RNS :

"
Synairgen is now close to completing a Phase II study in chronic obstructive pulmonary disease (COPD) patients with confirmed respiratory viral infections and pre-existing significant impairment of lung function. With 109 out of a target 120 participants already dosed, this trial has been paused to minimise the chance of vulnerable patients being exposed to further infection risk and to minimise distraction for respiratory staff in the UK hospitals and GP sites conducting the trial, who will be at the forefront in dealing with patients suffering from COVID-19. We are currently exploring ways to adapt the trial to enable patients in the pre-treatment pool to be dosed if they become infected with SARS-CoV-2.
"

@Ghia : Thanks for that information. Best for everyone in the long run if the trial is conducted with discretion.

Interesting rise today - something in the portfolio must be doing well?

Some people moving profits from NCYT perhaps.

@Manifesto " the FACT that China succesfully treated patients with the same drug"

It is not the same drug - see posts earlier today.

Positive RNS for RMS/Gyrometric

https://www.investegate.co.uk/remote-monitored-sys--rms-/rns/cloudveil-and-gyrometric-update/202004080700051350J/

Sorry Mookster, I don't understand the differences between IFN alpha & beta well enough to make a judgement! But nobbygnome on ad vfn has relevant qualifications and says "beta interferon is arguably the best interferon for delivery into the lungs".

Thanks Lp160606, fascinating document!

Glad it makes clear that it's interferon-alpha, not SNG001, because there's been a lot of confusion here about that.

Hi Mac57, good find. Is this the same article that you saw in the printed edition? :

https://www.dailymail.co.uk/health/article-8193277/Is-answer-coronavirus-chemists-shelves.html

@wetdream "Didn’t think China was very supportive of IP."

Yes, the Chinese violation of IP at an everyday level is legendary; I have personal experience of it at a tech company I used to work for.

But I don't think they'd flaunt the rules in something as public as this. After all, if they really want this IP then I'm sure they can afford to buy it!

For info, here is a post by nobbygnome on that other BB on 04/04/20 :

"
>> the patient investor Ok to try to answer some of your questions about interferons. All the interferons are related proteins but have distinctly different sequences. For example beta has only 31% identity with the family of alphas. The alphas and beta all bind to the same receptor proteins so clearly that is the part of the molecules where the identity is very similar. However, the fact that they all bind to the same receptor doesn't mean they all have the same action. That is because they are produced by different cells and so the temporal and spatial appearance of the molecules is not the same. Beta is produced by fibroblasts whereas the alphas are produced by white blood cells. There are lots of fibroblasts in the lung which is why beta interferon is most likely to be the important family member in anti viral responses in the lung. But overall I must stress the immune system is extremely complex and it is difficult to assign absolute rules. There is an awful lot of redundancy and overlap which is why multiple approaches have a chance of working. However, I stand by my assertion that beta interferon is arguably the best interferon for delivery into the lungs.
"

The Chines/Cuban product is interferon-alpha.

The following may help explain what this was all about :

http://www.aktiencheck.de/news/Artikel-FRA_New_Instruments_available_on_XETRA_06_04_2020_002-11159631

We seem to have been included in "XETRA", which is some sort of electronic trading system used by the Frankfurt SE & others.

Good to see them finally realising that their payroll is too high.

"These changes right-size the organisation ..."

Not sure about that, but it's a step in the right direction.

All I'm suggesting is follow the links and look at the original source. Why isn't interferon mentioned there?

@Sacrabbeatle : OK, but my link is also linked from there - it looks like the original source?

Hi @kajo99. It's a bit confusing, because according to this :

https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1

it was a combination of danoprevir + ritonavir, with interferon not mentioned.

Maybe some mix-up in the Stanford database?